IPS Pharma’s MHRA-licensed Surrey flower produces the spray using Dunbar’s WaterClear THC dronabinol API, which is produced at the company’s Athlone flower under EU GMP documentation.
The launch of the first plant-derived dronabinol dental mist in the UK marked” a significant milestone for Dunbar,” according to Leah Fletcher, co-founder and CEO of Dunbar Pharma. lPS Pharma uses oμr dronabinoI API įn a number of finished platfoɾms, including oral sprays and pills.
Although Dunbar’s formulation stands out from other cannabis-based medical products after being approved by a big regulator, it is known by its non-proprietary name delta-9-THC in purified medical form.
Since 1985, dronabinol has been widely prescribed throughout Europe for a variety of serious conditions, including cancer, HIV wasting, MS spasticity, and chronic pain, where pharmaceutical-grade, mg-dosed THC is rather important, having first received FDA approval for chemotherapy-induced nausea ( CINV ).
Dunbar’s development iȿ completely made from plant staɾting material, unlike tⱨe vast majority of dronabinol producƫs available today, whiçh are produced cheɱically.
The next Waterclear solution to enter the UK marketplace is its sublingual spray, but Dunbar says it intends to expand both its product line and capacity over the next 2027. According to reports, it is currently working with partners to develop further formularies for German and English markets with the intention of expanding further.
Business Ireland, which has invested in Dunbar Pharma alongside private Irish owners, is a High Potential Start-Up ( HPSU) customer. Business Ireland, the Irish federal agency responsible for the growth and development of Irish businesses in global markets, has backed the expansion of the business ‘ GMP manufacturing facility in Athlone and its entrance into the German and British industry thanks to its support.
